1. A phase I, randomized, double‐blind study to assess the safety, tolerability and efficacy of the topical RORC2 inverse agonist PF‐06763809 in participants with mild‐to‐moderate plaque psoriasis. (14th September 2020) Authors: Berstein, G.; Zhang, Y.; Berger, Z.; Kieras, E.; Li, G.; Samuel, A.; Yeoh, T.; Dowty, H.; Beaumont, K.; Wigger‐Alberti, W.; von Mackensen, Y.; Kroencke, U.; Hamscho, R.; Garcet, S.; Krueger, J. G.; Banfield, C.; Oemar, B. Journal: Clinical and experimental dermatology Issue: Volume 46:Number 1(2021) Page Start: 122 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase I, randomized, double‐blind study to assess the safety, tolerability and efficacy of the topical RORC2 inverse agonist PF‐06763809 in participants with mild‐to‐moderate plaque psoriasis. (1st January 2021) Authors: Berstein, G.; Zhang, Y.; Berger, Z.; Kieras, E.; Li, G.; Samuel, A.; Yeoh, T.; Dowty, H.; Beaumont, K.; Wigger‐Alberti, W.; von Mackensen, Y.; Kroencke, U.; Hamscho, R.; Garcet, S.; Krueger, J. G.; Banfield, C.; Oemar, B. Journal: Clinical and experimental dermatology Issue: Volume 46:Number 1(2021) Page Start: 122 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗